Deals Of The Week Road Tests Biopharma’s Options
Executive Summary
The industry has pulled back on experimentation with option-to-license deals; results have been mediocre and biotechs, no longer as cash-strapped as they were in 2009, when option deals peaked, have other … options. Plus deals by Roche, Endo, Pfizer, GSK and others.